Takumoto, Yuki http://orcid.org/0000-0001-9191-3494
Shiroiwa, Takeru
Shimozuma, Kojiro
Iwata, Hiroji
Takahashi, Masato
Baba, Shinichi
Kobayashi, Kokoro
Hagiwara, Yasuhiro
Kawahara, Takuya
Uemura, Yukari
Mukai, Hirofumi
Taira, Naruto
Sawaki, Masataka
Funding for this research was provided by:
Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation, Japan
Article History
Accepted: 1 February 2022
First Online: 1 March 2022
Declarations
:
: This study was funded by the Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation, Japan. All decisions concerning the planning, implementation, and publication of this study were made by the executive committee of this study. The corporate and individual sponsors of this study are listed on the CSPOR website (ExternalRef removed).
: HI has a potential conflict of interest with Chugai Pharmaceutical Co. Ltd, Pfizer Inc, and Sanofi S.A. MT has a potential conflict of interest with Chugai Pharmaceutical Co. Ltd.
: Our data are available only on the CSPOR data center.
: Not applicable.
: This study was one of the secondary endpoints in the RESPECT trial, which was a randomized, open-label clinical trial. The study protocol of the RESPECT trial conformed with the guidelines of the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of Japan’s Ministry of Health, Labor, and Welfare. It was approved by an independent ethics committee for each participating site. All participants provided written informed consent.
: We used data from the RESPECT trial, which obtained informed consent from the respondents under those conditions.
: Not applicable.
: YT and TS were involved in the conception and design of the study. All authors contributed to the analysis or interpretation of data for this work, contributed in drafting or revising it critically for important intellectual content, and approved the final version.